CN109475571A - 治疗下尿路尿道上皮癌的方法 - Google Patents

治疗下尿路尿道上皮癌的方法 Download PDF

Info

Publication number
CN109475571A
CN109475571A CN201780040391.1A CN201780040391A CN109475571A CN 109475571 A CN109475571 A CN 109475571A CN 201780040391 A CN201780040391 A CN 201780040391A CN 109475571 A CN109475571 A CN 109475571A
Authority
CN
China
Prior art keywords
antimetabolite
individual
bladder
gemcitabine
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780040391.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·吉辛
C·库蒂
P·萨玛
C·拉里沃-埃尔金斯
C·瑟西
V·阿加瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liris Biomedical Inc
Original Assignee
Taris Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Inc filed Critical Taris Biomedical Inc
Priority to CN202410626384.1A priority Critical patent/CN118453872A/zh
Publication of CN109475571A publication Critical patent/CN109475571A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CN201780040391.1A 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法 Pending CN109475571A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410626384.1A CN118453872A (zh) 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US62/333,151 2016-05-06
US201762443614P 2017-01-06 2017-01-06
US62/443,614 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410626384.1A Division CN118453872A (zh) 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法

Publications (1)

Publication Number Publication Date
CN109475571A true CN109475571A (zh) 2019-03-15

Family

ID=60203435

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780040391.1A Pending CN109475571A (zh) 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法
CN202410626384.1A Pending CN118453872A (zh) 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410626384.1A Pending CN118453872A (zh) 2016-05-06 2017-05-05 治疗下尿路尿道上皮癌的方法

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP4209221A1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR102435709B1 (enExample)
CN (2) CN109475571A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL295592A (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ787786A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG11201809838VA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
IL274343B2 (en) 2017-11-08 2023-10-01 Taris Biomedical Llc Treatment methods and maintenance treatment for bladder cancer using gemcitabine
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
MY188911A (en) * 2010-06-02 2022-01-13 Abraxis Bioscience Llc Methods of treating bladder cancer
PT2600800T (pt) 2010-08-05 2020-11-05 Taris Biomedical Llc Dispositivo de administração de drogas por stent ureteral, kit e método
KR20140048086A (ko) 2011-02-04 2014-04-23 타리스 바이오메디컬 인코포레이티드 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스
KR20190134832A (ko) 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
CN104812395A (zh) 2012-08-31 2015-07-29 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
ES2902833T3 (es) * 2012-08-31 2022-03-30 Taris Biomedical Llc Sistemas y métodos de administración de fármacos para el tratamiento de cáncer de vejiga que comprenden oxaliplatino
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
SG10201708522SA (en) 2013-03-15 2017-12-28 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
MX391755B (es) 2013-03-15 2025-03-21 Taris Biomedical Llc Dispositivos de administración de medicamentos y métodos para administración de medicamentos.
CN113413537A (zh) 2013-08-19 2021-09-21 塔里斯生物医药公司 多单元药物递送装置和方法
CN114306899A (zh) 2014-06-26 2022-04-12 塔里斯生物医药公司 包含弹性聚合物-药物基质系统的膀胱内药物递送装置及方法
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C. ANANDADAS等: "Bladder Preservation by Neoadjuvant Chemotherapy followed byConcurrent Chemoradiotherapy with Gemcitabine in Muscle invasive Bladder Cancer (MIBC)", 《CLINICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
SG11201809838VA (en) 2018-12-28
US20190388338A1 (en) 2019-12-26
MX389296B (es) 2025-03-20
KR20190005204A (ko) 2019-01-15
NZ748252A (en) 2025-10-31
LT3452053T (lt) 2023-02-10
IL262746B (en) 2022-09-01
KR102435709B1 (ko) 2022-08-25
SMT202300047T1 (it) 2023-03-17
RS64032B1 (sr) 2023-04-28
EP4209221A1 (en) 2023-07-12
PL3452053T3 (pl) 2023-05-08
EP3452053A1 (en) 2019-03-13
CN118453872A (zh) 2024-08-09
JP7712055B2 (ja) 2025-07-23
WO2017193098A1 (en) 2017-11-09
ES2940227T3 (es) 2023-05-04
IL262746A (en) 2018-12-31
FI3452053T3 (fi) 2023-04-12
EP3452053B1 (en) 2022-12-14
HUE060965T2 (hu) 2023-04-28
RU2018142908A (ru) 2020-06-08
EP3452053A4 (en) 2019-12-25
SG10201913416PA (en) 2020-03-30
RU2018142908A3 (enExample) 2020-08-31
AU2017261371B2 (en) 2023-07-06
JP2022009327A (ja) 2022-01-14
KR20220123317A (ko) 2022-09-06
MX2018013432A (es) 2019-08-12
BR112018072551A2 (pt) 2019-02-19
NZ787824A (en) 2025-10-31
MX2021013461A (es) 2021-12-10
IL295592A (en) 2022-10-01
SI3452053T1 (sl) 2023-03-31
PT3452053T (pt) 2023-03-03
AU2017261371A1 (en) 2018-12-13
HRP20221544T1 (hr) 2023-02-17
JP2019514970A (ja) 2019-06-06
JP2024028881A (ja) 2024-03-05
NZ787786A (en) 2025-10-31
CA3023274A1 (en) 2017-11-09
RU2022100624A (ru) 2022-02-09
RU2764747C2 (ru) 2022-01-20

Similar Documents

Publication Publication Date Title
JP2024028881A (ja) 下部尿路上皮がんを処置する方法
JP2022022392A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
US20250108000A1 (en) Implantable nanochannel delivery devices
US12059428B2 (en) Methods of treating tumor metastasis
JP2019514970A5 (enExample)
US20200060966A1 (en) Methods of treating overactive bladder using trospium
HK40005970A (en) Method of treating lower tract urothelial cancer
HK40005970B (en) Method of treating lower tract urothelial cancer
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
BR112018072551B1 (pt) Kits para tratamento de câncer de bexiga músculo invasivo
RU2832085C2 (ru) Способы лечения гиперактивного мочевого пузыря с применением троспия хлорида

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315

RJ01 Rejection of invention patent application after publication